The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2008
Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Das Bibhuti, Shoemaker Lawrence, Recto Michael, Austin Erle, Dowling Robert
Аннотация
Despite increasing clinical experience in adult transplantation, induction therapy with alemtuzumab (Campath-1H) has rarely been reported in pediatric solid-organ transplants, and has been limited to kidneys, intestine and multi-visceral organs. Basic science research and clinical observations reported from the adult experience suggest potential benefits of alemtuzumab in pediatric organ recipients. We report successful induction therapy with alemtuzumab and steroid-free maintenance therapy for cardiac transplantation in a teenager, and discuss its merits in this patient.
Предметные рубрики MeSH
AdolescentAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmCardiomyopathy, DilatedDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesGraft RejectionHeart FailureHeart TransplantationHumansImmunosuppressive AgentsPostoperative CareRisk AssessmentTransplantation ImmunologyTransplantation, HomologousTreatment Outcome